Phaseline

Companies › Chiesi Farmaceutici

Chiesi Farmaceutici: clinical trials, targets and expected readouts

10 active drug programs in 17 registered trials: 8 Phase 2, 5 Phase 3, 3 Phase 1, 1 Phase 4; Respiratory, Other, Metabolic and endocrine, Psychiatry; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Formoterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 4AsthmaJun 2028
Metreleptin
Leptin receptor agonist
LEPRPhase 3Partial Lipodystrophy; Familial Partial Lipodystrophy; Lipodystrophy; Anorexia Nervosa …Mar 2028
CHF 5993 100/6/12.5 μg pMDI HFA-152a
Triple combination of inhaled corticosteroid, long-acting beta-2 agonist, and long-acting
ADRB2, CHRM3Phase 3AsthmaOct 2028
Oleogel-S10
Topical gel containing plant-based ingredients for wound healing
–Phase 3Epidermolysis BullosaSep 2029
CHF5993 pMDI 100/6/12.5 µg with HFA-152a
Triple combination: inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), long-
ADRB2, CRHR1Phase 2AsthmaJun 2027
PRX-102
Recombinant human alpha galactosidase-A (pegunigalsidase alfa)
GLAPhase 2Fabry DiseaseOct 2027
CHF10067 (Zampilimab)
TNF-α inhibitor monoclonal antibody
TNFPhase 2Idiopathic Pulmonary FibrosisJun 2028
CHF6467–Phase 1Healthy VolunteersFeb 2027
CHF10136–Phase 1AsthmaDec 2027
CHF6333–Phase 1Bronchiectasis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05164341MetreleptinPhase 3Partial LipodystrophyMetabolic and endocrineJul 2026
NCT06166056CHF6333Phase 1BronchiectasisRespiratoryAug 2026
NCT06305182MetreleptinPhase 2Anorexia NervosaPsychiatryDec 2026
NCT07163182CHF6467Phase 1Healthy VolunteersOtherFeb 2027
NCT07301736CHF5993 pMDI 100/6/12.5 µg with HFA-152aPhase 2AsthmaRespiratoryJun 2027
NCT02262832MetreleptinPhase 3LipodystrophyMetabolic and endocrineJul 2027
NCT02262806MetreleptinPhase 2DiabetesMetabolic and endocrineJul 2027
NCT05710692PRX-102Phase 2Fabry DiseaseMetabolic and endocrineOct 2027
NCT07851623CHF10136Phase 1AsthmaRespiratoryDec 2027
NCT06679270MetreleptinPhase 3Familial Partial LipodystrophyMetabolic and endocrineMar 2028
NCT07666490FormoterolPhase 4AsthmaRespiratoryJun 2028
NCT07516951CHF10067 (Zampilimab)Phase 2Idiopathic Pulmonary FibrosisRespiratoryJun 2028
NCT06328608PRX-102Phase 2Fabry DiseaseMetabolic and endocrineOct 2028
NCT05351164MetreleptinPhase 2Lipomatosis, Multiple SymmetricalMetabolic and endocrineOct 2028
NCT07546981CHF 5993 100/6/12.5 μg pMDI HFA-152aPhase 3AsthmaRespiratoryOct 2028
NCT06917690Oleogel-S10Phase 3Epidermolysis BullosaOtherSep 2029
NCT00085982MetreleptinPhase 2Severe Insulin ResistanceMetabolic and endocrineJan 2030

From the company's SEC filings

Complete response letters from FDA

Targets

ADRB2 (3) CRHR1 (1) GLA (1) LEPR (1) CHRM3 (1) TNF (1)

Companies with the same targets

AstraZeneca GSK Novartis Teva Branded Pharmaceutical Products R&D Bristol-Myers Squibb Lunan Better Pharmaceutical Actimed Therapeutics ARS Pharmaceuticals Polarean EyeD Pharma

Companies built like this

Teva Branded Pharmaceutical Products R&D Valenta Pharm JSC Shanghai Synvida Biotechnology Shionogi Vicore Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.